New Product Lunch TSUMIS®Carfilzomib


Bioprofarma Bagó is pleased to present the launch of the product TSUMIS® carfilzomib, for its Hematology Line.

TSUMIS® carfilzomib is approved by ANMAT, in combination with daratumumab and dexamethasone, lenalidomide and dexamethasone or dexamethasone alone, for the treatment of adult patients with multiple myeloma who have received at least one prior treatment.

TSUMIS® carfilzomib is available in a single form of a pack containing a 60 mg. lyophilised vial.

TSUMIS® carfilzomib joins the portfolio of products for the treatment of multiple myeloma, together with MIASOMA® bortezomib and MYELENZ® lenalidomide.

This new treatment alternative comes to give specialists more options for the care of their patients.

We invite you all to take a look at a short literature to learn more about this launch!

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

26th ARGENTINE CONGRESS OF HEMATOLOGY organized by the Argentine Society of Hematology

Bioprofarma Bagó participated in the 26th Argentine Congress of Hematology 2023, which was held from November 1st to the 4th at its two venues: the Sheraton Hotel and the Costa Galana Hotel, in the City of Mar del Plata.

New Product Launch VETRANO®palbociclib

We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.